Assessment of an Automatic Closed-loop Insulin Delivery System

Not Applicable

Completed

• Conditions: Diabetes Mellitus, Type 1
• Interventions: Device: Automatic closed-loop insulin delivery; Device: Control

• Registration Number: NCT02366767
• Lead Sponsor: Stanford University

Brief Summary

The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Detailed Description

This study will be completed in two parts.

The initial part of this study will be an inpatient evaluation of the system with the primary goal of assessing safety and feasibility. This will involve 8 subjects with type 1 diabetes, aged 14 - 40 years, admitted for up to 60 hour. Plasma glucose levels will be collected hourly and tested by YSI (YSI 2300, Yellow Springs Instrument). These studies will be performed at Stanford University and will include group sporting activities to mimic the diabetes camp environment. Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise, and prebed by subjects with research staff supervision during the day and at 00:00, 03:00 and 07:00 by research staff. These data will be reviewed by the DSMB before proceeding to camp studies.

The second part of this study will be to test the efficacy of the system during diabetes summer camps. We will test the system in subjects with type 1 diabetes, aged 14-40 years, attending diabetes camp. There will be 20 subjects recruited, with 10 subjects randomized to the control arm Medtronic 530G system with threshold suspend (control group) and 10 subjects randomized to the automatic closed-loop insulin delivery (intervention group). Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise and prebed by subjects with research staff supervision and at 00:00, 03:00 and 07:00 by research staff. The primary aim of this study is to generate preliminary data of system safety and efficacy in a closely supervised environment that challenges glucose control.

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2014-06-26
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Study First Submitted QC: 2015-02-11
• Study First Posted: 2015-02-19
• Results First Submitted: 2015-10-28
• Results First Submitted QC: 2016-12-12
• Status Verified: 2017-02
• Results First Posted: 2017-02-06
• Last Update Submitted: 2017-02-09
• Last Update Posted: 2017-03-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Clinical diagnosis of type 1 diabetes

   • The diagnosis of type 1 diabetes is based on the investigator's judgment
   • C peptide levels and antibody determinations are not required

2. Daily insulin therapy for ≥ 12 months

3. Insulin pump therapy for ≥ 3 months

4. Age 14.0 - 40.0 years

5. Subject comprehends written English

6. Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD

7. Female subjects past menarche must have a negative urine pregnancy test

8. Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age

9. For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.

Read More

Exclusion Criteria

1. Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
2. Diabetic ketoacidosis in the past month
3. Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months
4. Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
5. Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
6. Subject has a history of liver or kidney disease (other than microalbuminuria)
7. Subject has active Graves' disease
8. Subjects with inadequately treated thyroid disease or celiac disease
9. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
10. Subject has a history of diagnosed medical eating disorder
11. Subject has a history of known illicit drug abuse
12. Subject has a history of known prescription drug abuse
13. Subject has a history of current alcohol abuse
14. Subject has a history of visual impairment which would not allow subject to participate
15. Subject has an active skin condition that would affect sensor placement
16. Subject has adhesive allergies
17. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
18. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
20. Subject is currently on beta blocker medication
21. Subject is currently participating in another investigational study (drug or device)
22. Subject is deemed by the investigator to be unwilling or unable to follow the protocol
23. Presence of a febrile illness within 24 hours of enrollment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
automatic closed-loop insulin delivery	Automatic closed-loop insulin delivery	The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
Control	Control	The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.

Primary Outcome Measures

Name	Time	Method
Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes	6 days	1. As measured by the number of events of plasma glucose values ≤ 50 mg/dL OR frequency of system alerts preceding a plasma glucose value of ≤ 50 mg/dL in all subjects; 2. As measured by the number of events of system alerts of plasma glucose values \>300 mg/dL lasting for more than one hour in all subjects.; 3. As measured by number of events of serum ketones \>3 mmol/L in all subjects; 4. As measured by the number of events meeting the criteria for severe hypoglycemia, defined as hypoglycemic seizure, loss of consciousness or coma or an event requiring administration of glucagon or IV glucose in all subjects

Secondary Outcome Measures

Name	Time	Method
Feasibility of Using the Automatic Closed Loop Delivery System in Adolescents and Adults With Type 1 Diabetes	6 days	1. As measured by the system initiating and operating properly for at least 75% of the time for 75% of subjects.; 2. As measure by the completion of study enrollment procedures and education on system use within 2 hours for 75% of the subjects.
Efficacy of Hybrid Closed-loop System in Comparison With Control	6 days	As measured by overall mean sensor glucose percent time in range 70-180 mg/dL.

Trial Locations

Locations (3)

Packard El Camino Hospital; 🇺🇸 Mountain View, California, United States

Camp Conrad-Chinnock; 🇺🇸 Angelus Oaks, California, United States

Lucile Packard Children's Hospital; 🇺🇸 Palo Alto, California, United States